Rezolute (RZLT) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.18

Estimate

-$0.18

Surprise

+2.7%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Rezolute (RZLT) reported adjusted EPS of -$0.18, in line with the -$0.18 estimate.

• Rezolute, Inc. Reports First Quarter Fiscal 2027 Financial Results — fiscal.ai, 2026-11-05
• Rezolute Files Prospectus For Offering $400M Mixed Shelf — benzinga, 2026-11-05
• Rezolute Q1 EPS $(0.18), Inline — benzinga, 2026-11-05

TrendMatrix currently rates RZLT Hold at 5.2/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +2.7% surprise compares with a -7.2% four-quarter average. Next scheduled report: 2027-02-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$3.88

Price target

$8.53

Stop

$3.61

Upside to target

+119.8%

Reward-to-risk

8.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$375.3M

P/E (fwd)

-8.3

52-week range

$1.07–$11.46

Off 52-week high

66.1%

RSI (14)

55

Volume vs avg

1.18×

Score today

5.2/10